James N. Ingle

TL;DR: The efficacy of the AR antagonist, bicalutamide (B) is tested for patients with AR+/ER-/PR- MBC in a multicenter Phase II trial to better characterize this subtype of breast cancer.

TL;DR: In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide, doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to that three-drug combination, and the new combination (T-CAP) was evaluated in patients with advanced adenocarcinoma of the lung.

TL;DR: It is concluded that menogaril administered by the method that was employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy and does not preclude response to subsequent treatment with doxorubicin.

TL;DR: Prospective studies using hormone measurements to define menstrual cycle status more accurately than the reported day of the menstrual cycle could provide further insight about the postulated association.